Search

In an extraordinary demonstration of excellence, positive results from two separate studies of new therapies for the treatment of advanced melanoma were presented at the plenary session of the 2011 annual meeting of the American Society of Clinical Oncology by Paul Chapman, MD, and Jedd Wolchok MD, PhD, members of Memorial Sloan Kettering Cancer Center's Melanoma and Sarcoma service, and lead authors on the studies along with collaborators from more than a one hundred cancer centers worldwide.

… Sunday, June 5, 2011 In an extraordinary demonstration of excellence, positive results from two separate studies of new therapies for the treatment of advanced melanoma were presented at the plenary session of the 2011 annual meeting of the American Society of Clinical Oncology by Paul Chapman, MD, and

Larotrectinib, a highly selective TRK kinase inhibitor, shows rapid, potent, and durable efficacy in both adult and pediatric patients with solid tumors that harbor TRK fusions, regardless of tumor type or patient age, according to results from three clinical trials published in the New England Journal of Medicine. The landmark data support the foundation of precision oncology by creating a treatment option for a genetically defined cancer while continuing to validate the concept that comprehensive molecular profiling should be strongly considered in people of all ages with advanced solid tumors.

… Wednesday, February 21, 2018 Bottom Line: Larotrectinib, a highly selective TRK kinase inhibitor, shows rapid, potent, and durable efficacy in both adult and pediatric patients with solid tumors that harbor TRK fusions, regardless of tumor type or patient age, according to results from three clinical

Memorial Sloan Kettering Cancer Center and Summit Medical Group together announce a new collaborative relationship for the care of people with cancer.

… Thursday, October 2, 2008 Memorial Sloan Kettering Cancer Center (MSKCC) and Summit Medical Group (SMG) together announce a new collaborative relationship for the care of people with cancer. The initiative will give New Jersey residents who have cancer greater access to a broad array of services offered

MSK is helping young patients navigate their journey and get the best treatment through specialized counseling, digital connections, and more. “The gratitude I feel is so deep. I’m not just alive; I’m living,” says Desiree Allen.

… Friday, October 1, 2021 Before she was diagnosed with cancer in 2020 at age 31, Desiree Allen was living her best life. “I was in school part-time and working full-time, and I was — and still am — in a long-term relationship,” says the cardiology nurse, now 32. “As a matter of fact, I was having the

In this online discussion, panelists give tips for managing both your physical and mental well-being during the holiday season, especially against the backdrop of the ongoing pandemic.

… Tuesday, December 21, 2021 On Wednesday, December 15, 2021, a panel of Memorial Sloan Kettering Cancer Center (MSK) experts joined the Abyssinian Baptist Church in an online discussion that provided guidance and tips on staying mentally and physically healthy amid uncertainty, especially during this

The U.S. Food and Drug Administration has approved vimseltinib for adult patients with a rare condition called tenosynovial giant cell tumor, based on a trial led by an MSK researcher.

… Wednesday, February 19, 2025 The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM ) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue that lines the joints.  Sarcoma oncologist William Tap, MD , Chief of the

Luis Diaz Jr., MD, Head of the Division of Solid Tumor Oncology, and incumbent of the Grayer Family Chair, and Kojo S.J. Elenitoba-Johnson, MD, Chair of the Department of Pathology and Laboratory Medicine, Member in the Human Oncology Pathogenesis Program (HOPP), and the incumbent of the James Ewing Alumni Chair of Pathology at Memorial Sloan Kettering Cancer Center (MSK), have been elected to the National Academy of Medicine (NAM), one of the highest honors bestowed upon scientists worldwide.

… Tuesday, October 10, 2023 Luis Diaz Jr., MD , Head of the Division of Solid Tumor Oncology, and incumbent of the Grayer Family Chair, and  Kojo S.J. Elenitoba-Johnson, MD , Chair of the Department of Pathology and Laboratory Medicine, Member in the Human Oncology Pathogenesis Program (HOPP), and the

New findings from researchers at the Sloan Kettering Institute suggest that cancer causes may be lurking in the molecule that bridges DNA and protein.

… Monday, August 27, 2018 Summary Researchers at the Sloan Kettering Institute have found that changes in an information-carrying molecule called messenger RNA can inactivate tumor-suppressing proteins and thereby promote cancer. The findings pinpoint previously unknown drivers of the disease. IMPORTANT

New research led by investigators at Memorial Sloan Kettering Cancer Center identifies three genes that specifically mediate the metastasis, or spread, of breast cancer to the brain and illuminates the mechanisms by which this spread occurs.

… Wednesday, May 6, 2009 New research led by investigators at Memorial Sloan Kettering Cancer Center (MSKCC) identifies three genes that specifically mediate the metastasis, or spread, of breast cancer to the brain and illuminates the mechanisms by which this spread occurs. The study was published online

Meet Carmen Mendez, a perioperative nurse liaison at Memorial Sloan Kettering Cancer Center who is driven by compassion and empathy for the family members of patients undergoing surgery.

… Thursday, September 30, 2021 Carmen Mendez’s professional life began out of love for her mother. Love was the driving force behind her decision to go to nursing school. Now, as perioperative nurse liaison for the Josie Robertson Surgery Center , she is driven by compassion and empathy for the family